Skip to main content
. 2021 Nov 10;11:734853. doi: 10.3389/fonc.2021.734853

Figure 5.

Figure 5

The combination of anti-PD-1 therapy with DSF improves antitumor activity. (A) BALB/c mice were inoculated s.c. with 4T1 cells. Seven days after inoculation, mice began to receive DSF (i.g., daily, 100 mg/kg), anti-PD-1 blocking antibodies (i.p., four times, 2 mg/kg), a combination of reagents or solvent control as indicated. (B) Representative photographs of 4T1 tumor of the mice after treatment with DSF and/or anti-PD-1 blocking antibody. (C) 4T1 implanted tumor-bearing mice were randomly enrolled in different treatment groups as indicated. For each treatment group, tumor volumes were measured every 3 days and plotted individually. (D) The positive percentage of CD3, CD4, CD8, PD-L1, and granzyme B in 4T1 tumors. (E) The positive percentage of DNMT1 and IRF7 in 4T1 tumors. (F) Immunohistochemical staining for CD3, CD4, CD8, PD-L1, granzyme B, DNMT1, and IRF7 in 4T1 tumors. *p < 0.05, **p < 0.01, ***p < 0.001. ns, no statistic significance.